Remix Therapeutics to Present Preclinical Data Demonstrating MYB mRNA Degradation in AML at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

07 Dec 2023
www.prnewswire.com
ASHsiRNA
Data support the therapeutic potential of REM-422, a first-in-class MYB mRNA degrader
Oral dosing of REM-422 in MYB-dysregulated AML PDX models shows robust antileukemic activity
WATERTOWN, Mass., Dec. 7, 2023 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address underlying drivers of disease, today announced an upcoming presentation introducing REM-422, the Company's potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers. Data describing the activity of REM-422 in AML xenograft models will be highlighted at the 65th American Society of Hematology Annual Meeting and Exposition (ASH), taking place from December 9-12, 2023 in San Diego. Results demonstrate oral dosing of REM-422 degrades MYB mRNA, inducing anti-leukemic activity in multiple xenograft models.
"These compelling data support the therapeutic rationale of targeting MYB with REM-422 as a potential treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix Therapeutics. "REM-422 is the first compound entering the clinic from the REMaster discovery platform and we look forward to the start of clinical development in patients with MYB-dysregulated malignancies."
Lead author Charles Kung, PhD, Vice President of Biology, concludes "MYB is an important oncogenic transcription factor that is dysregulated in the majority of AML and MDS patients and we look forward to bringing REM-422 to patients in need of new treatment options."
Details for the poster presentation are as follows:
Title: REM-422, a potent, selective, oral small molecule mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in mouse xenograft models of AML
Abstract Number: 1425
Session Name: Poster Session I - Presentations
Session Date and Time: Saturday, December 9, 2023, 5:30 PM-7:30 PM
Session Location: Poster Hall
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix's innovative therapeutic approach has the potential to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.
SOURCE Remix Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.